Wacker Biotech GmbH is “THE MICROBIAL CDMO” – your partner of choice for process development and commercial manufacturing of biopharmaceuticals (proteins, vaccines and live microbial products) using microbial hosts. WACKER’s integrated service portfolio covers molecular biology, process- and analytical development as well as GMP manufacturing of biologics for clinical and commercial supply.
Wacker Biotech has more than 20 years of experience as a CDMO for vaccines using microbial hosts. Our expertise in manufacturing vaccines extends to the process development and manufacturing of a variety of vaccine products, including live attenuated, inactivated, (conjugated) polysaccharide and protein-based vaccines. Wacker Biotech has produced and released more than 650 GMP vaccine batches for clinical (phase I to III) and commercial applications. In 2020, Wacker Biotech entered into a manufacturing partnership for an mRNA-based COVID-19 vaccine candidate.